Intuitive Surgical (NSDQ:ISRG) dropped more than 11% today as Wall Street reacted to the surgical systems maker’s disappointing 1st-quarter earnings.
Wall Street Beat
Allergan resists $47B offer by swallowing poison pill
FDA clears Intuitive Surgical’s single-site da Vinci Sp robotic surgery system
Intuitive Surgical (NSDQ:ISRG) shares recouped some recent losses today after the medical device company announced 510(k) clearance from the FDA for its da Vinci Sp single-site robot-assisted surgery platform in urological procedures.
K2M’s IPO could reap as much as $183M
K2M Group Holdings, the largest privately held spinal implant maker, said today that its forthcoming initial public offering could be worth up to $183 million.
K2M announced its plans for a U.S. IPO early this year, saying in March that the launch could be worth $100 million.
Vital Therapies aims even lower with $12-per-share IPO | MassDevice.com On Call
MASSDEVICE ON CALL — California biotherapeutics company Vital Therapies dropped its per-share price even lower, opening today at $12 per share in the hopes of raising $54 million. Shares are slated to open today on the Nasdaq market under the symbol "VTL."
Cardiac Dimensions closes $20M equity round
Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.
M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, according to a press release. Investors in Australia, the U.S. and Canada also participated, the company said.
Mainstay Medical readies European IPO
Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.
Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.
Baxter blows away Wall Street as renal sales surge in Q1
GE Healthcare’s Q1 sales, profits slide
GE Healthcare (NYSE:GE) saw its sales and profits decline by single digits during the 1st quarter due to "market volatility.”
GE Healthcare posted profits of $570 million on sales of $4.20 billion for the 3 months ended March 31, for a bottom-line decline of 4.2% and a top-line slide of 2.1% compared with the same period last year.
Ex-Stryker exec dodges jail in insider trading scheme
Vital Therapies prices $54M IPO
Vital Therapies priced its initial public offering at $12 per share, once again lowering the bar for its 1st public flotation after scuttling its 1st try at a U.S. IPO.
Vital Therapies, which is developing a bio-artificial liver, last October set the IPO’s price range at $16-$18. But the San Diego-based company but shelved the offering until March, when it set the range at $13-$15 per share.